Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes

Trial Profile

Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN 5
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 13 Jun 2017 Post-hoc analysis of SUSTAIN 1-5 trials evaluating the proportion of subjects who achieved a composite endpoint of both greater than or equals 1% HbA 1c reduction and greater than or equals 5% weight loss; results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 The efficacy of semaglutide vs. comparators by baseline HbA 1c subgroup evaluated in a post-hoc analysis of SUSTAIN 1-5 trial; results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results of a post analysis of SUSTAIN 1-5 trials evaluating reductions in HbA 1c levels and body weight across BMI subgroups presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top